Adults studied for microneedle radiofrequency with low-dose isotretinoin were people in their 20s and 30s with inflammatory acne and acne scars already taking isotretinoin. People who were not studied include pregnant patients, children under 12, and recent systemic-therapy users excluded from one microneedle trial. Fractional microneedle radiofrequency uses tiny needles to deliver heat energy into skin for acne and scars. Low dose means 0.1-0.5 mg per kg per day for moderate or persistent acne under the 2026 ERAISE consensus.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was included in the combination studies?
- Who was not studied or cannot use isotretinoin?
- What improved with combined treatment?
- What should you check before asking about it?
Who was included in the combination studies?
A retrospective study included 71 patients with inflammatory acne and acne scars treated with fractional microneedle radiofrequency plus ablative fractional laser. Forty-three were taking low-dose isotretinoin or had stopped it within three weeks, according to the Integrative Dry Needling summary. Dermatology Advisor reporting on Kim et al.
gives mean age as 24.8 years, range 19-38, with 53.5 percent women Dermatology Advisor report. A prospective randomized trial enrolled 42 patients with moderate-to-severe acne already on isotretinoin for at least two months. Researchers assigned them to concurrent fractional radiofrequency, isotretinoin alone, or delayed radiofrequency after stopping isotretinoin, as reported by Dermatology Times Dermatology Times report. Thirty-eight patients finished that six-month follow-up period.
Who was not studied or cannot use isotretinoin?
A single-microneedle radiofrequency acne trial excluded recent systemic therapy users. The ICH-GCP registry for NCT04213638 lists exclusion of oral isotretinoin within six months and oral antibiotics within one month ICH-GCP registry entry. It also excluded recent anti-acne treatment or trial participation. U.S.
labeling limits isotretinoin to nonpregnant patients age 12 and older with severe recalcitrant nodular acne, according to National Library of Medicine DailyMed. Eligible acne involves multiple 5-mm or greater inflammatory nodules unresponsive to conventional therapy including systemic antibiotics. Isotretinoin is contraindicated in pregnancy because fetal exposure can cause severe birth defects, per the FDA prescriber guide. Patients who can become pregnant must avoid pregnancy before, during, and for one month after therapy under iPLEDGE controls.
What improved with combined treatment?
Inflammatory-lesion counts and Scar Global Assessment scores fell significantly in the retrospective cohort. Scar improvement was greater in the concomitant isotretinoin subgroup described by Dermatology Advisor reporting on Kim et al.
Thirty-eight completers had greater acne-scar volume reduction and better ECCA scores and satisfaction with concurrent isotretinoin plus fractional radiofrequency. Delayed treatment and isotretinoin alone improved less in that Dermatology Times-reported trial.
What should you check before asking about it?
The 2026 ERAISE consensus accepts 0.1-0.5 mg per kg per day for moderate or persistent acne PubMed Central consensus text. It reserves 0.5-1 mg per kg per day for severe disease. The same consensus warns of higher relapse without extended or maintenance therapy and advises metabolic laboratory monitoring.
Use your history to see if you resemble studied patients. A dermatologist can weigh persistent acne, scar type, isotretinoin timing, pregnancy plans, and lab follow-up. Bring that medication and pregnancy list to your visit.
- Compare your pattern: inflammatory acne with scars, not mild comedonal acne alone.
- List isotretinoin start date, dose, stop date, plus antibiotics in the past month.
- Confirm pregnancy status and prevention plan for before, during, and one month after therapy.
- Ask about metabolic labs and extended or maintenance therapy to lower relapse risk.
You Might Also Like
- Cumulative Isotretinoin Dose and Acne Relapse in a 2026 Trial: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Treatment Response in the 2026 Cumulative Isotretinoin Dose Trial: What the Findings Mean for Adults With Persistent Acne
- The 36-Patient Acne Laser Pilot Published in 2026: Safety and Monitoring Questions for Adults With Persistent Acne